Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Women's Cancer
- Inst for Women's Health
- Faculty of Pop Health Sciences
Dr John Timms is group leader of the UCL Institute for Women's Health Cancer Proteomics Group with 15 years of experience in proteomic method development and application and 19 years in cancer and cell signalling research. The group has expertise in the preparation, separation, characterisation and quantification of peptides and proteins using mass spectrometry and other methods. The group was one of the first users of 2D-DIGE technology which is now routinely used for protein expression profiling. The group has established platforms for linking high-throughput sample preparation with MS-based profiling of clinical samples for biomarker discovery and extensive experience in LC-based protein/peptide separations linked with tandem MS and mass-tagging for quantification.
Research is focused on understanding the molecular basis of cancer and cell signalling mechanisms and the identification of novel cancer biomarkers.
* Serum biomarker discovery - the group has developed high-throughput proteomic techniques aimed at identifying biomarkers of cancer using large case control clinical and pre-clinical sample collections. Work also involves assay development and validation of markers for the early detection of different cancer types.
* Molecular basis of breast and epithelial ovarian cancer - the group has combined gene expression and proteomic profiling methods with gene-specific knockdown to functionally characterise alterations in tumour tissues and cell models of breast and ovarian cancer.
* Mechanisms of cellular signalling - research is aimed at understanding the molecular events associated with growth factor and stress signalling in cells and how these are related to cancer development. This includes mapping proteomic responses to EGF and HRG growth factors and ErbB2/HER2 overexpression in mammary luminal epithelial cell models, characterising redox stress responses in cell models and delineating kinase networks using phosphoproteomic methods.
The group is also a member of the UCL Proteomics Technology Platform which aims to provide access and expertise in proteomic technologies to researchers across UCL. Our goal is to establish a core resource in proteomics, to provide technical expertise and knowledge in proteomic applications and data interpretation, to promote interaction between clinical and basic scientists and to provide training for the next generation of proteomics researchers.
PhD supervisor (7 past students; 2 present). Host and project supervisor to 3 visiting students on travelling fellowships. Supervisor to MSc and undergraduate project students. Contributed lectures on Proteomics, Mass spectrometry and Cancer Biology to undergraduate and MSc students.
|01-MAY-2012||Honorary Senior Lecturer||Faculty of Medical and Human Sciences||University of Manchester, United Kingdom|
|01-MAR-2003 – 30-NOV-2006||Lecturer (Joint Appointment)||Department of Biochemistry and Molecular Biology||UCL, United Kingdom|
|02-MAR-2002 – 30-NOV-2006||Associate Member and Group Leader||Cancer Proteomics||Ludwig Institute for Cancer Research UCL Branch, United Kingdom|
|01-MAR-1999 – 01-MAR-2002||Postdoctoral Research Fellow||Cancer Biochemistry||Ludwig Institute for Cancer Research UCL Branch, United Kingdom|
|01-NOV-1995 – 28-FEB-1999||Postdoctoral Research Fellow||Cancer Biology||Harvard Medical School, United States|
|1995||DPhil||Doctor of Philosophy||University of Oxford|
|1991||BA Hons||Bachelor of Arts (Honours)||University of Oxford|